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Background: Toll-like receptors (TLRs) enable innate immune cells to respond to pathogen- and host-derived
molecules. The central nervous system (CNS) exhibits most of the TLRs identified with predominant expression in
microglia, the major immune cells of the brain. Although individual TLRs have been shown to contribute to CNS
disorders, the consequences of multiple activated TLRs on the brain are unclear. We therefore systematically
investigated and compared the impact of sole and pairwise TLR activation on CNS inflammation and injury.
Methods: Selected TLRs expressed in microglia and neurons were stimulated with their specific TLR ligands in
varying combinations. Cell cultures were then analyzed by immunocytochemistry, FlowCytomix, and ELISA. To
determine neuronal injury and neuroinflammation in vivo, C57BL/6J mice were injected intrathecally with TLR
agonists. Subsequently, brain sections were analyzed by quantitative real-time PCR and immunohistochemistry.
Results: Simultaneous stimulation of TLR4 plus TLR2, TLR4 plus TLR9, and TLR2 plus TLR9 in microglia by their
respective specific ligands results in an increased inflammatory response compared to activation of the respective
single TLR in vitro. In contrast, additional activation of TLR7 suppresses the inflammatory response mediated by the
respective ligands for TLR2, TLR4, or TLR9 up to 24 h, indicating that specific combinations of activated TLRs
individually modulate the inflammatory response. Accordingly, the composition of the inflammatory response
pattern generated by microglia varies depending on the identity and combination of the activated TLRs engaged.
Likewise, neuronal injury occurs in response to activation of only selected TLRs and TLR combinations in vitro.
Activation of TLR2, TLR4, TLR7, and TLR9 in the brain by intrathecal injection of the respective TLR ligand into
C57BL/6J mice leads to specific expression patterns of distinct TLR mRNAs in the brain and causes influx of
leukocytes and inflammatory mediators into the cerebrospinal fluid to a variable extent. Also, the intensity of the
inflammatory response and neurodegenerative effects differs according to the respective activated TLR and TLR
combinations used in vivo.
Conclusions: Sole and pairwise activation of TLRs modifies the pattern and extent of inflammation and
neurodegeneration in the CNS, thereby enabling innate immunity to take account of the CNS diseases’ diversity.
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The family of Toll-like receptors (TLRs) comprises germ-
line encoded pathogen recognition receptors that allow
the innate immune system to differentiate among micro-
organisms by sensing their conserved motifs called
pathogen-associated molecular patterns [1]. Although
signaling pathways are shared by different TLRs, several
factors constitute the complexity of TLR function and
outcome. First, the subcellular distribution of the recep-
tors differs. Whereas TLRs 1, 2, and 4 to 6 primarily, but
not exclusively, localize to the plasma membrane, the class
of nucleotide sensing TLRs 3 and 7 to 9 are primarily
associated with intracellular vesicular compartments such
as endosomes [2]. Secondly, TLRs modulate antigen-
specificity by forming homo- and heterodimers (e.g., TLR1/
2, TLR2/6) and by adapting co-receptors and binding pro-
teins (e.g., TLR4/CD14/MD2). Thirdly, TLRs are activated
by a myriad of diverse agonists. Intracellular TLRs sense
nucleic acid-based agonists, such as dsRNA, ssRNA, and
unmethylated cytosine-phosphate-guanine motifs (CpG
ODN), thereby being particularly specialized in viral rec-
ognition. In contrast, TLRs expressed on the cell surface
detect lipopeptides, glycolipids, and flagellin derived from
a large variety of organisms including bacteria, parasites,
and fungi. Finally, engagement of TLRs by their cognate li-
gands leads to the recruitment of one or more of five
intracellular adaptor proteins, including myeloid differenti-
ation primary response gene 88 (MyD88) and TIR-domain-
containing adaptor inducing IFN-β (TRIF). MyD88 is
required for all TLR signaling pathways except TLR3
and a TLR4/MyD88-independent pathway. One major
TLR-induced set of responses is the activation of tran-
scription factors, such as NF-κB, leading to the induction
of proinflammatory mediators and type I interferons [1].
TLRs do not only recognize pathogen-associated molecular
patterns (PAMPs) but also host-derived damage-associated
molecular patterns (DAMPs). DAMPs identified as TLR
ligands include heat shock protein 60 (HSP60) and fi-
brinogen for TLR4 as well as gangliosides and hyaluronic
acid fragments for TLR2 [3]. Most of these molecules are
derived from extracellular matrix or are released by in-
jured cells, making them accessible to TLRs, and thereby
provoke inflammation during pathologies. This setting
may contribute to both infectious and non-infectious cen-
tral nervous system (CNS) injury [4].
All cells of the CNS express TLRs, while each cell type
displays its own subset of differentially expressed TLRs
and related signaling adaptor proteins [5-10]. The dynamic
expression of TLRs, some of which appears on certain cell
types only in specific settings, implicates their participation
and functional relevance in both physiological and
pathological states of the CNS [9,11,12]. In particular,
TLRs and associated signaling pathways contribute to
various CNS diseases such as infection, stroke, classicalneurodegenerative diseases, and multiple sclerosis [13,14].
In general, CNS disorders are characterized by inflamma-
tion and neuronal injury. Inflammation and tissue damage
exert the beneficial effect of clearance of pathogens, cell
debris, and other harmful components released from in-
jured cells thereby restoring homeostasis and enabling re-
pair. However, exaggerated activation of innate immunity
in the brain can cause further tissue damage, thereby ex-
acerbating the initial brain insult [15,16]. Activation of
TLRs in microglia, the major players in the innate im-
mune surveillance within the brain, results in secretion of
neurotoxic molecules such as cytokines and reactive oxy-
gen species in vitro [17,18]. The concept of receptor re-
dundancy for an effective innate immune response is still
comprehensible, especially in the brain, given the potential
for invading pathogens or cellular disturbances to cause
significant damage in a tissue with only limited regenera-
tive capacity.
It is conceivable that in a specific setting within a
physiological or pathological context in the CNS, more
than one TLR ligand is present and multiple TLRs are
activated simultaneously at one time. As the various
TLRs and TLR complexes may trigger specific intracel-
lular pathways, the signal resulting from the activation
of a specific TLR or a specific combination of TLRs may
induce a response individually suited for the respective
cause of TLR activation. To systematically investigate
and compare the impact of sole TLR activation and
combined TLR activation on CNS inflammation and in-
jury, we stimulated selected TLRs expressed in microglia
and neurons with their highly specific pathogen-
associated and host-derived ligands in varying combina-
tions in vitro and in vivo. Our results indicate that the
extent and pattern of the subsequent inflammatory re-
sponse and neuronal injury in the CNS varies specifically




C57BL/6J mice were purchased from Charles River,
Sulzbach, Germany. TLR4 knock out (TLR4KO) mice were
generously provided by Dr. S. Akira (Osaka University,
Department of Host Defense, Osaka, Japan). All animals
were maintained according to the guidelines of the com-
mittee for animal care. Experimental procedures were
performed in accordance with the institutional review
committee Landesamt für Gesundheit und Soziales, Berlin.
TLR ligands
Lipopolysaccharide (LPS), Pam3CysSK4, loxoribine, imi-
quimod, and CpG ODN were obtained from Invivogen,
San Diego, USA. HSP60 was obtained as low-endotoxin
charge from Enzo Life Sciences, Lörrach, Germany. Dose
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formed in microglial and neuronal cultures analyzed by
TNF-α ELISA (Additional file 1: Figure S1A) and by
quantification of NeuN+ cells per field (Additional file 1:
Figure S1B), respectively. The concentrations of the re-
spective ligands that induce maximum responses were in
part published in previous work [7,18,19] and were used
in this study.Primary culture of purified microglia
Purified microglia were generated from forebrains of 0- to
3-day-old mice as described previously [20]. For analysis
of the inflammatory response in vitro, microglia were
plated at 3 × 104 cells/96-well.Primary cultures of neurons and co-cultures of neurons
and microglia
Purified neurons were generated from mouse embryos at
gestational stage 17 as described previously [20]. Cells
were plated on glass cover slips treated with poly-d-lysine
at 5 × 105 cells/24-well in 500 μL. After 24 h, half of the
medium was replaced with fresh pre-warmed medium.
Purity of cultures was at least 96% after plating as veri-
fied by immunostaining with NeuN and glial fibrillary
acidic protein (GFAP) antibodies (both obtained from
Chemicon, Temecula, USA) and IB4 (Invitrogen, Carls-
bad, USA). For co-cultures, microglia were added to
DIV3-neurons at 6 to 7.5 × 104 cells/24-well in 500 μL.TNF ELISA
TNF-α concentrations in cell culture supernatants were
measured by enzyme-linked immunosorbent assay (ELISA)
using the BD OptEIA™ Set Mouse TNF (BD Biosciences,
San Diego, USA) according to the manufacturer’s manual.Multiple analyte detection
Multiple analyte detection of cytokines and chemokines
in supernatants and cerebrospinal fluid (CSF) was per-
formed using FlowCytomix (Bender MedSytems, Burlin-
game, USA). The immunoassay is a bead-based method to
detect the concentrations of up to 20 analytes in one sam-
ple using a flow cytometer. The mouse/rat basic kit was
used in combination with mouse simplex kits. Inflamma-
tory mediators analyzed by FlowCytomix assay included
TNF-α, CXCL1, CCL2, CCL5, IL-6, IL-10, IL-4, IL-17,
IFN-γ, IL-12p70, IL-13, IL-1α, GM-CSF, and IL-23.Analysis of nitric oxide (NO) content
The nitric oxide (NO) content was measured indirectly
by assaying the stable end product nitrite with the standard
Griess reaction, as previously described [18].Quantification of CNS cells in vitro
Co-cultures were quantified 3 days after starting the re-
spective incubation. For analysis of neuronal survival,
cell cultures were immunostained with NeuN antibody.
NeuN+ cells were quantified in 6 to 10 fields (at 600×
magnification) per coverslip, and the mean was calcu-
lated. Data are expressed as relative to control (=100%).
Caspase-3-positive cells (activated caspase-3 Ab, Millipore,
Darmstadt, Germany) were quantified in 6 to 10 fields (at
100× magnification) per coverslip, and the mean was cal-
culated. All quantifications were performed in a blinded
manner.
Intrathecal injection into mice
Intrathecal injection into mice and analysis of the CSF
were performed as described previously [7,16,19]. In de-
tail, 40 μL of ligand solution (PCR studies after 12 h: 10
μg LPS, 10 μg Pam3CysSK4, 10 μg imiquimod, 10 μg
CpG ODN; histologic studies after 72 h: 10 μg LPS, 40
μg Pam3CysSK4, 136 μg loxoribine, 10 μg CpG ODN,
all obtained from Invivogen, or 10 μg HSP60 (Enzo Life
Sciences) were injected intrathecally into 6- to 8-week-
old male mice. Notably, the contamination with LPS of
the HSP60 preparation as declared by the manufacturer
was <50 EU/mg and ≤1.67 EU/mg, as determined by an
independent laboratory specializing in endotoxin testing
and published in previous work (Mikrobiologisches Labor,
Münster, Germany; see also [18]). For real-time PCR ana-
lysis, brains were removed and cut along the sulcus med-
ianus into two halves, which were separately snap-frozen
in liquid nitrogen. For immunohistochemical studies, mice
were perfused transcardially with isotonic-saline followed
by 4% paraformaldehyde (PFA). Brains were removed,
subjected to a row of 10%, 20%, and finally 30% sucrose in
0.1 M phosphate buffered saline (PBS) for cryoprotection,
frozen in 2-methylbutan on dry ice, and stored at –80°C
until sectioning.
Real-time PCR
One brain hemisphere was homogenized in 1 mL TRIzol®
(Invitrogen, Darmstadt, Germany) with an Ultra-Turrax®
at 21,500 rpm for 30 sec. The homogenate was centri-
fuged at 12,000× g and 4°C for 15 min. DNA was removed
with RQ1 RNase-free DNase (Promega, Madison, USA)
and UltraPure™ phenol:chloroform:isoamyl alcohol (Invi-
trogen). For synthesis of cDNA from 1 μg RNA, random
hexamers (Roche, Mannheim, Germany) were used with
MMLV-RT (Promega). SYBR® Green-based quantitative
real-time PCR was performed with the RT2 qPCR Primer
Assays (SABiosciences Corporation, Frederick, USA)
according to the manufacturer’s manual with the RT2
Real-Time™ PCR protocol (#1) and the ABI7500 default
dissociation stage. Glyceraldehyde-3-phosphate dehydro-
genase was used as a housekeeping gene due to the fact
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statistics, dCT values (CTgene of interest – CTHKG) were log2-
transformed according to [21]. Fold exchange (2-(ddCT))
of treated mice relative to control was calculated using
the median of each group.
Immunohistochemistry
Coronal brain sections of five representative levels
(interaural 6.60 mm, 5.34 mm, 3.94 mm, 1.86 mm,
and –0.08 mm) were fixed with 4% PFA, washed with
PBS, and treated with blocking solution (PBS + 0.1%
Triton-X 100 + 5% normal goat serum) for 1 h. They were
then incubated with the primary antibody (anti-NeuN,
anti-neurofilament, anti-GFAP, all purchased from
Chemicon, Temecula, USA; Iba1 purchased from WAKO,
Richmond, USA; activated caspase-3 Ab, Millipore, Darm-
stadt, Germany) at 1:1,000 overnight at 4°C. Subsequently,
sections were incubated with the relevant secondary anti-
body (all purchased from Jackson Immuno Research,
West Grove, USA) for 1 h at room temperature. Nuclei
were stained with DAPI.
Quantification of CNS cells in vivo
Cells in brain sections were quantified 3 days after the
respective intrathecal injection into mice. For analysis of
neuronal survival sections were stained with NeuN anti-
body or an antibody against activated caspase-3. NeuN+
or caspase-3+ cells were counted in three fields (at 600×
magnification) of the cerebral cortex per hemisphere at
interaural 1.86 mm, and the mean was calculated, which
is expressed as NeuN+ or caspase-3+ cells per mm2. For
further analysis of apoptotic cells, sections were stained
by DAPI. Glial cells were quantified by staining brain
sections with Iba1 or GFAP antibodies to mark microglia
and astrocytes, respectively. Iba1- and GFAP-positive
cells were quantified and calculated as described above.
All quantifications were performed in a blinded manner.
Statistical analysis
Data are expressed as indicated in the figures. Statistics
as indicated in the figure legends were calculated using
GraphPad Prism version 5.01 for Windows (GraphPad
Software, San Diego, USA). Differences were considered
statistically significant when P <0.05.
Results
Pairwise stimulation of TLRs induces an inflammatory
response in microglia that differs from sole TLR activation
in vitro
In immune cells, stimulation of TLRs with their respect-
ive specific ligands initiates the canonical signaling path-
way, which results in activation of transcription factors,
including NF-κB, and ultimately leads to the secretion of
proinflammatory molecules [1]. Microglia constitutivelyexpress mRNA of most of the TLRs identified so far [22].
Since it is well established that microglia readily release
TNF-α upon TLR stimulation [16,23], we used the ana-
lysis of TNF-α production as a functional assay to eluci-
date the inflammatory response in microglia induced by
single versus combined TLR stimulation. To this end,
microglia isolated from C57BL/6J mice were incubated
with LPS as a highly specific ligand for TLR4, Pam3-
CysSK4 as a specific TLR2 agonist acting mainly through
TLR2/1 heterodimeric receptors, loxoribine as a ligand for
TLR7, or CpG ODN as a TLR9-specific agonist solely or
in pairwise combination, as indicated, for up to 72 h. The
concentrations of the ligands were based on dose response
experiments in microglia and neurons (see Methods
section) and comply with well-established working doses
described in other studies [24-27].
Supernatants of microglial cultures were collected at
indicated time points and subjected to ELISA to meas-
ure TNF-α concentrations (Figure 1). Each of the four
TLR ligands named above induced secretion of TNF-α
from microglia. However, a direct comparison between
the TNF-α levels induced by the different TLRs is not
feasible due to the differing properties and concentrations
of the various ligands. TNF-α amounts in supernatants of
unchallenged microglia were low or undetectable during
the whole round of observation (Figure 1). Simultaneous
challenge of microglia with LPS plus Pam3CysSK4, thereby
activating TLR4 and TLR2, respectively, led to an additive
increase in TNF-α release from 3 h on to 72 h, which was
significant compared to both single application of LPS and
Pam3CysSK4 at 12 h and 24 h. Simultaneous stimulation
of microglia with LPS plus CpG ODN, thereby activating
TLR4 and TLR9, respectively, induced significant additive
levels of TNF-α from 12 h to 72 h compared to sole
stimulation of TLR4 or TLR9. The combination of Pam3-
CysSK4 plus CpG ODN, thereby activating TLR2 and
TLR9, respectively, resulted in a slight increase of TNF-α
amounts compared to sole stimulation of TLR2 or TLR9
(Figure 1). TNF-α levels in response to simultaneous
stimulation with two different ligands remained higher
than levels after stimulation with single ligands even
when double doses of the respective individual TLR
ligand were used (data not shown). Thus, simultaneous
stimulation of TLR2 plus TLR4, TLR4 plus TLR9, and
to a lesser extent TLR2 plus TLR9, which all belong to
the bacteria sensing TLR family, resulted in prolonged
elevated TNF-α secretion compared with the stimulation
of the respective single receptor. In contrast, activation of
the virus sensing TLR7 with loxoribine additionally to the
stimulation with LPS, Pam3CysSK4, or CpG ODN sup-
pressed TNF-α secretion induced by sole stimulation with
the respective ligand to levels induced by loxoribine alone
from 3 h on to 24 h. However, at 72 h, simultaneous stimu-
lation of TLR4 and TLR7 induced significant additive levels
Figure 1 Activation of single and pairwise TLRs results in a distinct inflammatory response in microglia. Purified microglia were
stimulated with LPS (100 ng/mL), Pam3CysSK4 (Pam, 100 ng/mL), loxoribine (lox, 1 mM), or CpG ODN (CpG, 1 μM) alone or simultaneously with
pairwise combinations of the ligands, as indicated. PBS served as control. Supernatants were collected at indicated time points and analyzed by
TNF-α ELISA; mean ± SEM of five independent experiments run with duplicates. Two-way ANOVA with Bonferroni-selected pairs of each individual
compound vs. combination of compounds (*LPS vs. ligand combination; #Pam vs. ligand combination; †CpG vs. ligand combination; §lox vs.
ligand combination). P*, #, †, § <0.05; P**, ##, ††, §§ <0.005; P***, ###, †††, §§§ <0.001.
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(Figure 1). Similar results were obtained using imiquimod
as a further TLR7-specific ligand (data not shown).
To test whether activation of TLR3 (Additional file 2:
Figure S2A) exerts similar inhibitory effects on TNF-α
secretion induced by other TLR ligands as was observed
for TLR7, microglia were incubated with the respective
ligands named above alone or in combination with poly
(I:C), a TLR3-specific ligand, or loxoribine. Resulting su-
pernatants were analyzed by ELISA for TNF-α secretion
after 6 h (Additional file 2: Figure S2B). Additional treat-
ment with poly(I:C) did not affect the TNF-α response
induced by Pam3CysSK4, LPS, or CpG ODN alone, while
additional treatment with loxoribine suppressed these re-
sponses, as expected. Further studies revealed that super-
natants of microglia incubated with loxoribine did not
contain significant amounts of interferon (IFN)-α, a major
type I IFN, which can be induced by activation of TLR7 in
peripheral immune cells [1] (data not shown). In line with
these findings, inhibitory effects mediated by TLR7 activa-
tion were not affected by the presence of an inhibitory
antibody against IFN-α/β receptor I (data not shown).
In summary, stimulation of a single TLR and simultaneous
stimulation of two TLRs result in distinct inflammatory
responses in microglia.
Simultaneous activation of two TLRs results in a distinct
cytokine and chemokine profile in microglia
To characterize the inflammatory pattern induced by
sole and pairwise TLR activation, the production of fur-
ther cytokines and chemokines in microglia was deter-
mined by the bead-based assay FlowCytomix. Since the
effect of simultaneous TLR stimulation on microglial acti-
vation in terms of TNF-α secretion was most prominent
at 24 h, as described above, this incubation time was
chosen in this experimental set-up (Figure 2A). Except for
the anti-inflammatory cytokine IL-10, which was pro-
duced in response to TLR2, TLR4, and TLR9 activation,
but not detected after activation of TLR7, individual
stimulation of TLR2, TLR4, TLR7, and TLR9 induced a
similar pattern of cytokines and chemokines including
TNF-α, CXCL1, CCL2, IL-6, and CCL5, although to a dif-
ferent extent (Figure 2A). In contrast, IL-4, IL-17, IFN-γ,
IL-12p70, IL-13, IL-1α, GM-CSF, and IL-23 were not de-
tected in response to activation of any TLR tested during
the time of observation (data not shown). Simultaneous
stimulation of TLR4 plus TLR2 as well as TLR4 plus
TLR9 led to additive levels of IL-6 and significant additive
levels of IL-10 compared to activation of the respective
single TLR. Activation of both TLR2 plus TLR4 and TLR2
plus TLR7 suppressed the production of CXCL1 compared
to activation of TLR2 alone, whereas simultaneous activa-
tion of TLR2 plus TLR9 led to increased CXCL1 levels
compared to sole activation of TLR9. In contrast, none ofthe pairwise ligand combinations led to significant modified
expression levels of CCL2 or CCL5 compared to appli-
cation of the respective single ligand. In general, co-
stimulation of TLR7 tended to suppress the release of
TNF-α, IL-6, CXCL1, and IL-10 induced by TLR4,
TLR2, and TLR9 activation alone (Figure 2A). In super-
natants of cells stimulated with agonists for TLR2 and
TLR9, protein expression levels of all six analytes
equaled the levels resulted from sole stimulation with
Pam3CysSK4, suggesting that TLR2 signaling overruled
that of TLR9 (Figure 2A).
TLR signaling also results in transcription of the enzyme
NO synthase. Microglia activated by LPS release NO,
which reveals toxic effects on neurons [17,28]. To further
unravel the effect of sole and pairwise TLR stimulation on
microglia, the amount of NO was measured in the re-
spective supernatants by Griess reaction (Figure 2B). Rele-
vant amounts of NO were not detected within 48 h after
both activation of TLR4 alone and simultaneous TLR
stimulation with LPS (data not shown). After 48 h, co-
stimulation of TLR7 diminished NO secretion caused by
activation of TLR4 alone, and co-stimulation of TLR4 plus
TLR2 or plus TLR9 led to additive NO release. Additional
stimulation of TLR2 significantly increased the release of
NO in response to TLR4 activation by more than 2.5-fold
by 48 h (Figure 2B) and up to 3-fold by 72 h (data not
shown). In comparison, the effect of combined activation
of TLR9 plus TLR4 was less pronounced with merely
1.5-fold more NO by 48 h (Figure 2B) and 72 h (data
not shown) compared to the respective single TLR
stimulation. Notably, the results in terms of NO re-
lease after stimulation of a single TLR versus two TLRs
matched those of TNF-α, IL-6, and IL-10 secretion, as
described above.
Taken together, pairwise stimulation of TLRs expressed
in microglia results, time-dependently, in a pattern of in-
flammatory molecules that differs from the one obtained
from activation of a single TLR.
Stimulation of TLR4 in microglia with host-derived and
pathogen-associated ligands leads to a distinct
inflammatory response
The stress protein HSP60 released from injured CNS
cells was identified as a host-derived ligand for TLR4 in
microglia [18]. We wondered whether the outcome of
TLR activation in microglia depends on the DAMP or
pathogen-associated nature of the TLR ligands used.
Thus, we repeated the experimental set-up using different
pathogen-associated TLR ligands, as described above, and
included the host-derived TLR4 ligand HSP60. In detail,
microglia were stimulated with HSP60 alone or in com-
bination with LPS (TLR4), Pam3CysSK4 (TLR2), loxor-
ibine (TLR7), or CpG ODN (TLR9). Supernatants were
analyzed for TNF-α content at several time points, as
Figure 2 (See legend on next page.)
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Figure 2 Pairwise TLR activation results in a distinct profile of cytokines and chemokines in microglia. Purified microglia were stimulated
with LPS (100 ng/mL), Pam3CysSK4 (Pam, 100 ng/mL), loxoribine (lox, 1 mM), or CpG ODN (CpG, 1 μM) alone or simultaneously with pairwise
combinations of the ligands, as indicated. PBS served as control. Supernatants were analyzed by (A) TNF-α ELISA (mean ± SEM of five independent
experiments run with duplicates) and flow cytometry-based multiple analyte detection for several cytokine/chemokine levels, as indicated
(mean ± SEM of four independent experiments) after 24 h, or by (B) Griess reaction for NO content (mean ± SEM of five independent
experiments run with duplicates) after 48 h. ANOVA with Bonferroni-selected pairs of each individual ligand vs. combination of ligands, as
indicated. P* <0.05; P** <0.005; P*** <0.001; n.d., not detected.
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microglia with LPS resulted in the release of TNF-α
during the whole round of observation (Figure 1),
stimulation of TLR4 with HSP60 did not result in sig-
nificant amounts of TNF-α secreted from microglia
compared to control conditions at any time point.
TNF-α levels remained unchanged in response to
stimulation of TLR4 plus TLR9 with HSP60 and CpG
ODN, respectively, and, surprisingly, of TLR4 with bothFigure 3 Impact of TLR4 activation by HSP60 on the inflammatory re
HSP60 (1 μg/mL), LPS (100 ng/mL), Pam3CysSK4 (Pam, 100 ng/mL), loxorib
pairwise combinations of the ligands, as indicated. Supernatants were analyze
two to four independent experiments run with duplicates) or (B) by flow cyto
indicated (mean ± SEM of three independent experiments run with duplic
Bonferroni-selected pairs of each individual compound vs. combination of co
P*, # <0.05; P** <0.005; P*** <0.001. Data in (B) were analyzed by ANOVA with
of compounds, as indicated. P* <0.05; P** <0.005; P*** <0.001; n.d., not detectHSP60 and LPS, compared with the respective single
application of the PAMP. In contrast, release of TNF-α
was increased in response to co-stimulation of TLR4
plus TLR7 with HSP60 and loxoribine compared to
HSP60 alone. Combined activation of TLR4 plus TLR2
with HSP60 and Pam3CysSK4, respectively, resulted in
an additive release of TNF-α compared to stimulation
of TLR2 alone (Figure 3A). Maximum differences re-
garding secretion of TNF-α between cells treated withsponse in microglia in vitro. Primary microglia were stimulated with
ine (lox, 1 mM), or CpG ODN (CpG, 1 μM) alone or simultaneously with
d (A) by TNF-α ELISA at various time points, as indicated (mean ± SEM of
metry-based multiple analyte detection for cytokine/chemokine levels, as
ates) after 12 h. Data in (A) were analyzed by two-way ANOVA with
mpounds (*HSP60 vs. ligand combination; #Pam vs. ligand combination).
Bonferroni-selected pairs of each individual compound vs. combination
ed.
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bination of Pam3CysSK4 and HSP60 were detected at
12 h (Figure 3A). Therefore, further analysis of the
cytokine and chemokine profile after stimulation of
TLR4 plus TLR2 with HSP60 and Pam3CysSK4, re-
spectively, was performed at this time point (Figure 3B).
Analysis of microglial supernatants by FlowCytomix re-
vealed statistically significant differences between the
combined stimulation with Pam3CysSK4 plus HSP60
and the respective single application regarding IL-6 se-
cretion as well as between the combined stimulation
and HSP60 alone regarding CXCL1 secretion. Further-
more, a trend towards increased secretion of CCL5 and
GM-CSF after incubation with Pam3CysSK4 plus HSP60
compared to the respective single application was ob-
served, although these results did not reach statistical
significance (Figure 3B).
These findings indicate that activation of TLR4 by
DAMPs and PAMPs leads to the induction of different
intracellular signaling pathways in microglia.
Co-stimulation of TLR4 and TLR2 in microglia causes
enhanced neuronal injury compared to stimulation of the
respective receptor alone
Activation of TLR4 in microglia leads to neuronal cell
death [20]. To investigate the impact of pairwise TLR ac-
tivation on neuronal injury, co-cultures of neurons and
microglia were exposed to the TLR ligands LPS (TLR4),
Pam3CysSK4 (TLR2), loxoribine (TLR7), or CpG ODN
(TLR9) alone, or to combinations of these ligands, as in-
dicated (Figure 4A). Subsequent immunocytochemistry
using NeuN antibody and IB4 revealed that all TLR li-
gands and ligand combinations tested resulted in loss
of neurons compared to control conditions, although
to a varying extent. To determine the neurotoxic effects’
dependency on microglia, purified neurons without micro-
glia were stimulated in parallel (Figure 4B). Quantification
of NeuN+ cells in co-cultures of neurons and microglia
confirmed the neurotoxic effects described above. Com-
parative analysis of co-cultures and neurons alone re-
vealed that LPS, Pam3CysSK4, and CpG ODN affected
neuronal survival solely when microglia were present
(Figure 4B), as expected [20,28,29]. In contrast, activa-
tion of TLR7 led to neuronal cell death in the absence
of microglia (Figure 4B) due to cell-autonomous neuro-
toxic effects mediated by the same receptor [7]. Simul-
taneous stimulation of TLR4 plus TLR2 in co-cultures
caused severe neurotoxicity reducing neuronal viability
to 26.3% ± 20.6 compared to control conditions. These
neurotoxic effects were significantly increased com-
pared to the effects induced by TLR2 or TLR4 activation
alone. Combined stimulation of TLR4 plus TLR9 showed
merely a trend in reducing neuronal viability compared to
the neuronal survival after stimulation of the respectivesingle TLR. All other combinations of TLR ligands, as in-
dicated, resulted in neuronal cell death to a similar extent
as it was observed in cell cultures incubated with the
respective ligand alone (Figure 4B). In addition, relative
microglial viability in the respective co-cultures incubated
with different TLR ligands and ligand combinations was
assessed (Figure 4B). Treatment with the TLR2-specific
ligand Pam3CysSK4 alone caused loss of microglia, as ex-
pected [30]. However, simultaneous stimulation of TLR2
plus TLR4 or TLR2 plus TLR9 led to a slight, but signifi-
cant increase of microglial numbers compared to sole
stimulation of TLR2. Treatment with CpG ODN, LPS,
and loxoribine, alone or in combination, did not affect
microglial viability compared to control conditions during
the observed time course.
Simultaneous activation of microglia by loxoribine, an
agonist for TLR7, and the DAMP HSP60, an agonist for
TLR4, causes enhanced neuronal injury compared to the
respective single application
Next, we aimed at determining the impact of simultaneous
TLR stimulation by pathogen-associated and host-derived
ligands on the viability of neurons. To this end, co-cultures
of neurons and microglia and neurons alone were stimu-
lated with different DAMPs and pathogen-associated li-
gands and their combinations, as indicated, and were
analyzed in terms of neuronal survival by immunocyto-
chemistry (Figure 5A). Co-cultures of microglia and neu-
rons incubated with the DAMP HSP60 plus the PAMP
LPS, both activating TLR4, showed a slight trend of in-
creased neuronal decay compared to the one induced by
the respective single stimulus. Whereas combined stimula-
tion of TLR4 plus TLR2 with LPS and Pam3CysSK4, re-
spectively, resulted in increased neurotoxicity compared to
the respective single application in co-cultures (Figure 4),
neurotoxic effects were unchanged in co-cultures chal-
lenged with HSP60 plus Pam3CysSK4, thereby activating
TLR4 and TLR2, compared with stimulation with the re-
spective ligands alone, although the same TLR, namely
TLR4, was involved (Figure 5A). Combination of the
DAMP HSP60 plus the TLR7 agonist loxoribine led to a
significant increase in neuronal cell death by a further
10% compared to the one induced by each ligand alone
(Figure 5A). Simultaneous incubation of co-cultures de-
rived from the same preparation analyzed above with high
doses of LPS (TLR4) plus loxoribine (TLR7) did not result
in increased neuronal cell death compared to the respect-
ive single challenge (Figure 5B). Thus, simultaneous acti-
vation of TLRs and subsequent neuronal injury may not
only be dependent on the TLR per se, but also on the
ligand engaged. Neurotoxic effects induced by HSP60
alone or in combination with the respective pathogen-
associated TLR ligand required the presence of micro-
glia regularly (Figure 5A). To confirm that the enhanced
Figure 4 Co-activation of TLR4 and TLR2 causes enhanced microglia-dependent neuronal injury in vitro. (A) Primary cortical neurons
were supplemented with purified microglia. Co-cultures were stimulated with 100 ng/mL LPS, 100 ng/mL Pam3CysSK4 (Pam), 1 mM loxoribine
(lox), or 0.1 μM CpG ODN (CpG) alone or with pairwise combinations of the ligands, as indicated. PBS served as control. After 72 h co-cultures
were immunostained with NeuN Ab (neurons, red) and IB4 (microglia, green). Scale bar, 100 μm. (B) Cortical neurons alone or supplemented with
microglia were incubated with the TLR ligands named above, as indicated. After 72 h, NeuN+ and IB4+ cells were quantified and expressed as
relative neuronal viability and relative microglial viability, respectively, as indicated. Each condition was performed in duplicate and averaged.
Mean ± SEM from four to five individual experiments with ANOVA followed by Bonferroni post-hoc test of control vs. each treatment and of
single vs. pair-wise stimulation (relative neuronal viability: co-cultures: *; neurons: †, relative microglial viability: co-cultures *), as indicated. Two-way
ANOVA with Bonferroni post-hoc test between indicated groups testing if the neurotoxic effect is dependent on microglia (#). P* <0.05; P** <0.005;
P*** <0.001; P# <0.05; P## <0.005; P### <0.001; P† <0.05; P†† <0.005.
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loxoribine were dependent on TLR4 expressed in micro-
glia, neurons were co-cultured with microglia derived from
mice lacking TLR4 (Figure 5C). As expected, in these cell
cultures, neurotoxicity induced by HSP60 alone was abol-
ished. Moreover, co-cultures containing microglia deficient
of TLR4 treated with the combination HSP60 plus loxori-
bine displayed similar neurotoxic effects as observed in cell
cultures incubated with loxoribine alone, confirming the
specificity of the respective TLR engaged. Immunostaining
of co-cultures containing wild-type microglia with an anti-
body against activated caspase-3 showed that stimulation
of TLR7 alone with loxoribine resulted in significantlyenhanced apoptosis compared to control conditions.
Combined stimulation with HSP60 plus loxoribine caused
a significant increase in cells positive for activated
caspase-3 compared with the single application of HSP60
(Figure 5D).
Expression of different TLR mRNAs in response to
activation of a single TLR in the brain
Expression of TLR mRNA in both immune cells and cells
of the CNS depends on the mode of infection, e.g., in-
duced by bacteria, viruses, or parasites [12,31]. Several
previous studies on infectious diseases indicate that mul-
tiple pattern recognition receptors act in concert to induce
Figure 5 Simultaneous activation of TLR4 by HSP60 and of TLR7 by loxoribine causes enhanced neuronal injury. Co-cultures of neurons
and microglia as well as neurons alone were stimulated with 1 μg/mL HSP60, 100 ng (A) or 1 μg (B) /mL LPS, 100 ng/mL Pam3CysSK4 (Pam), 1
mM loxoribine (lox), or 0.1 μM CpG ODN (CpG) alone or with pairwise combinations of the ligands, as indicated. PBS served as control. After 72 h,
NeuN+ cells (A-C) or after 24 h, cells positive for activated caspase-3 (D) were quantified and expressed as relative neuronal viability or
caspase-3+ cells/field, respectively. Each condition was performed in duplicate and averaged. Mean ± SEM from (A) three to four and (B, C) four
individual experiments with ANOVA followed by Bonferroni post-hoc test of control vs. each treatment and of single vs. pair-wise stimulation (*), as
indicated. (A) In addition, data were analyzed by two-way ANOVA with Bonferroni post-hoc test between indicated groups testing if effect is
dependent on microglia (#). (D) Mean ± SEM from four individual experiments with ANOVA followed by Bonferroni post-hoc test of control vs. each
treatment and of single vs. pairwise stimulation. Scale bar, 100 μm. P* <0.05; P** <0.005; P*** <0.001; P# <0.05; P## <0.005; P### <0.001.
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comprehensive study using intrathecal injection of differ-
ent specific TLR ligands into mice [19] to determine the
effect of the stimulation of a single TLR on the expression
of various TLR family members, the adapter MyD88, and
proinflammatory molecules, such as TNF-α and Il-1β, in
the CNS compared to control conditions in vivo. In detail,
brain tissue from mice injected intrathecally with LPS
(TLR4), Pam3CysSK4 (TLR2), imiquimod (TLR7), or CpG
ODN (TLR9) was analyzed by real-time PCR after 12 h
(Figure 6). Whereas intrathecal injection of the TLR4 lig-
and LPS resulted in an increase in the expression espe-
cially of TLR1 and TLR2 mRNA as well as of tnf and il1β,
injection of the TLR2 agonist Pam3CysSK4 led to an in-
crease in the expression especially of TLR1, TLR2, TLR8
mRNA, tnf, and il1β compared to control conditions.Activation of TLR7 caused an increase in the expression
especially of the endosome-related receptors TLR8 and
TLR9 mRNA, and stimulation of TLR9 resulted in up-
regulation especially of TLR1, TLR2, TLR8, TLR9 mRNA,
tnf, and il1β compared to control conditions. Expression,
especially of TLR3, TLR5, TLR6, TLR7, and MyD88
mRNA, was unaffected by stimulation of the respective
TLR. In general, expression of TLR4 mRNA was nearly
undetectable and did not change under any condition
(Figure 6). Also, mRNA expression levels of the TLR
downstream signaling molecules irak1, irak4, traf6, nf-κb,
the cytokines il4, il6, il10, and iNOS were undetectable
or very low under any condition and did not change in
response to intrathecal stimulation of any TLR com-
pared to control conditions (data not shown). Notably,
activation of a TLR in the CNS by its specific ligand did
Figure 6 mRNA expression of TLRs in response to activation of a single TLR in the CNS. C57BL/6J mice were injected intrathecally with 10
μg LPS (n = 9), 10 μg Pam3CysSK4 (Pam, n = 9), 10 μg imiquimod (Imi, n = 8), or 10 μg CpG ODN (CpG, n = 9). Intrathecal injection of 0.9% NaCl
(ctrl, n = 9) served as control. After 12 h, brain tissue was analyzed for mRNA expression of TLRs and proinflammatory molecules, as indicated, by
quantitative real-time PCR. Data are presented as delta CT (dCT = CTgene of interest – CTGapdh) of each mouse with median per group on reverse
scale to visualize changes in mRNA levels. Fold increase (2-ddCT, with fold change >2 and <0.5 expressing biological significance) was calculated
with the median of each group, setting the control to 1; ANOVA of log2 transformed dCT values followed by Bonferroni post-hoc test of control
vs. treatment. P* <0.05; P** <0.005; P*** <0.001.
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and therefore did not influence its own transcription
(Figure 6). However, in our experimental set-up, statis-
tical significance often did not reflect biological signifi-
cance of a group (defined as <0.5 and >2-fold
expression compared to control, respectively), due to
large variations of CT values among the injected mice.
In summary, activation of a single TLR in the brain re-
sults in up-regulation of a distinct pattern of TLR family
members and TLR-associated molecules in vivo.
Sole activation of TLR2, TLR7, and TLR9 in the CNS leads
to microglial activation and neuronal damage in vivo
We have utilized intrathecal injection of agonists highly
specific for the respective TLR to establish an experimen-
tal model in the mouse that accurately reflects neuronal
damage and neuroinflammation, providing an excellent
model system to investigate effects on the brain mediated
by activation of a single TLR [7,19]. Whereas TLR2 and
TLR4 mediate neuronal damage through activation of
microglia, activation of TLRs expressed in neurons, such
as TLR7, can cause cell-autonomous neuronal injury
in vitro [16]. To assess the impact of different activated
TLRs on inflammation and neurodegeneration in the
brain in vivo, the TLR ligands LPS (TLR4), Pam3CysSK4
(TLR2), loxoribine (TLR7), or CpG ODN (TLR9) were
injected intrathecally into mice. After 3 days, brain sec-
tions were immunostained with markers for neurons,
axons, and microglia to analyze neuronal survival and
microglial activation. Seven out of 9 mice injected with
loxoribine and 7 out of 10 mice injected with CpG ODN
revealed loss of neurons and axonal injury in the cerebral
cortex compared to control conditions, respectively
(Figure 7A). In both groups, especially in areas with re-
duced neurofilament-positive fibers, activated micro-
glia displayed a pronounced immunoreactivity for Iba1
and thicker processes compared to control conditions
(Figure 7A). Quantification of NeuN+ cells revealed that
upon stimulation of TLR7 or TLR9 neuronal numbers in
the cerebral cortex were reduced by 11.9% and 17%, re-
spectively (Figure 7B). Activation of TLR2 also resulted in
loss of neurons by 12.1%, although not reaching statistical
significance, and caused major injury of axons in 9 out of
11 mice (Figure 7A,B). Furthermore, microglia of brains
challenged by the TLR2 agonist displayed a distinct acti-
vated state (Figure 7A). Similarly, activated microglia in
the cerebral cortex were observed in response to intra-
thecal LPS. However, stimulation of TLR4 did not lead to
a significant decrease of neuronal numbers or major
axonal injury compared to control conditions (Figure 7A,B).
Immunostaining of brain sections with an antibody
against activated caspase-3 confirmed the induction of
apoptosis in the cerebral cortex of animals injected
with loxoribine and CpG ODN (Figure 7C).Infiltration of peripheral macrophages and leukocytes
into the brain is restricted until they are attracted by sig-
nals generated during infection or injury [34]. To assess
the inflammatory response in the periphery after activa-
tion of TLRs in the CNS in vivo, leukocytes in the CSF
of mice injected intrathecally with different TLR ligands
were quantified (Figure 7D). Whereas leukocytes were
absent in the CSF of control mice, intrathecal injection
of Pam3CysSK4 (TLR2), LPS (TLR4), imiquimod (TLR7),
and CpG ODN (TLR9) led to infiltration of leukocytes. By
comparison, the strongest influx was detected after injec-
tion of Pam3CysSK4 and CpG ODN. In contrast, intra-
thecal injection of imiquimod (Figure 7D) and loxoribine
(data not shown), both activating TLR7, or LPS, provoked
the recruitment of only minute numbers of leukocytes
into the CSF. CSF probes of mice injected intrathecally
with the TLR ligands named above were also analyzed by
FlowCytomix regarding the presence of various cytokines
and chemokines, as indicated, after 24 h (Figure 7E).
Whereas injection of the respective TLR agonist resulted
in undetectable or only minute amounts of CXCL1,
CCL5, and TNF-α, CCL2 secretion after injection of LPS
was significantly increased compared to control condi-
tions. IL-6 and IL-10 were not detected under any
condition.
In summary, activation of different TLRs in the CNS
leads to microglial activation, influx of peripheral im-
mune cells, secretion of distinct inflammatory mediators,
and neurodegeneration in varying degrees depending on
the specific TLR engaged in vivo.
Subsequent challenge with the DAMP HSP60, an agonist
for TLR4, does not modify neurodegeneration induced by
TLR2 or TLR7 in the CNS
Next, we addressed the question of whether stimulation
of TLRs by DAMPs, which are released from injured
cells [35], adds to previous or ongoing TLR-induced
CNS injury in vivo. We hypothesized that additional
activation of TLRs by DAMPs fuels the response of the
innate immune system induced by PAMPs, thereby ex-
acerbating tissue damage. In detail, the PAMPs Pam3-
CysSK4 (Figure 8A,B) or loxoribine (Figure 8C,D) were
injected intrathecally into mice, thereby stimulating
TLR2 and TLR7, respectively. Endotoxin-free water, in
which Pam3CysSK4 and loxoribine were dissolved, was
injected as a carrier control. After 24 h, animals received
an intrathecal injection of HSP60. PBS, in which HSP60
was dissolved, served as additional carrier control. After
a further 3 days, brains were subjected to immunohisto-
chemical analysis. Quantification of NeuN-positive cells
in the cerebral cortex revealed a significant loss of 9.3%
after injection of HSP60 (+water) and a tendential loss
of 4.4% and 5.7% in response to injection of Pam3CysSK4
(+PBS) and loxoribine (+PBS, P = 0.0652, Mann-Whitney
Figure 7 (See legend on next page.)
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Figure 7 Activation of specific TLRs causes neurodegeneration and inflammation in the brain in vivo. (A, B) C57BL/6J mice were injected
intrathecally with water (control, n = 7) or one of the four TLR ligands (10 μg LPS, n = 10; 40 μg Pam3CysSK4, Pam, n = 11; 136 μg loxoribine, Lox,
n = 9; 10 μg CpG ODN, CpG, n = 10), as indicated. After 3 days, brains were analyzed by immunohistochemistry. (A) Representative micrographs
of the cerebral cortex immunostained with NeuN Ab, neurofilament Ab, and Iba1 Ab to detect neurons, axons, and microglia, respectively. Scale
bar, 100 μm, inset 50 μm. (B) NeuN+ cells of the cerebral cortex were quantified. The mean of six high power fields per cerebral cortex is
expressed as NeuN+ cells per mm2; median with Kruskal-Wallis test followed by Bonferroni post-hoc test of control vs. treatment. P* <0.05;
P** <0.005. (C) Representative micrographs of the cerebral cortex immunostained with an Ab against activated caspase-3. Cortical cells positive
for activated caspase-3, as indicated by arrows, were quantified. The mean of six high power fields per cerebral cortex is expressed as caspase-3+ cells
per mm2; median with Kruskal-Wallis test followed by Bonferroni post-hoc test of control vs. treatment. P*** <0.001. (D) C57BL/6J mice were injected
intrathecally with 0.9% NaCl (control, n = 9) or one of the four TLR ligands (10 μg LPS, n = 9; 10 μg Pam3CysSK4, Pam, n = 9; 10 μg imiquimod, Imi,
n = 8; 10 μg CpG ODN, CpG, n = 9), as indicated. After 12 h, cerebrospinal fluid (CSF) was obtained from the cistern magna. Leukocytes in the CSF were
counted and are expressed as leukocytes per μL CSF. Median with Kruskal-Wallis test followed by Dunn’s multiple comparison test of control vs.
treatment. P* <0.05; P** <0.005. (E) C57BL/6J mice were injected intrathecally with 0.9% NaCl (control, n = 4) or one of the four TLR ligands (10 μg LPS,
n = 4; 10 μg Pam3CysSK4, Pam, n = 4; 10 μg loxoribine, Lox, n = 4; 10 μg CpG ODN, CpG, n = 4), as indicated. After 24 h, CSF was analyzed by flow
cytometry-based multiple analyte detection for amounts of various cytokines/chemokines, as indicated. Median with Kruskal-Wallis test followed by
Dunn’s multiple comparison test of control vs. treatment. P* <0.05.
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(water + PBS) (Figure 8A,C). Brains of mice that received
additional HSP60 after stimulation of TLR2 (Pam+
HSP60) or TLR7 (Lox +HSP60) displayed no significant
changes regarding neuronal survival in the cerebral cortex
compared to brains challenged by the respective single lig-
and (Figure 8A,C). Immunostaining of brain sections with
an antibody against activated caspase-3 confirmed the
induction of apoptosis in animals injected with HSP60
(+water) and the absence of additional degenerating ef-
fects compared to treatment with the respective single lig-
and if the ligand combinations named above were used
(Figure 8B,D). Also, we tested for the integrity of axons by
using an antibody against neurofilaments (Figure 8E,F). In
accordance with the results regarding neuronal viability in
the cerebral cortex described above, axonal injury was not
enhanced by the additional injection of HSP60 compared
to the respective single injection (Figure 8E,F).
Brains of animals treated with HSP60 (+water) showed
similar numbers and morphologic characteristics of
microglia compared with control conditions (Figure 8E,
F). In brains challenged by TLR2 stimulation (Pam +
PBS) less microglia compared to control conditions were
detected, and the morphology of these cells resembled a
resting state (Figure 8E). However, in this experiment,
mice were analyzed 24 h later than in the previous experi-
ment in which, on the contrary, distinct activation of
microglia was observed (Figure 7). Reduction in microglial
numbers after an extended time period might be a conse-
quence of TLR2-mediated microglial death [36]. Similar
morphologic characteristics of microglia were observed
in brains activated by TLR2 (Pam3CysSK4) plus TLR4
(HSP60) (Figure 8E). In animals injected with the TLR7
agonist loxoribine (Lox + PBS) or with a combination of
loxoribine plus the TLR4 agonist HSP60 microglia like-
wise displayed a resting state, and numbers of these cells
were decreased compared with control conditions and an-
imals treated with HSP60 (+water) (Figure 8F).Taken together, sole activation of TLR2 by PamCysSK4,
TLR7 by loxoribine, and TLR4 by its host-derived ligand
HSP60 cause neurodegeneration, whereas activation of
TLR4 by its pathogen-associated ligand LPS does not
significantly affect neuronal viability in vivo. Although
doses of the respective ligands and in particular timing,
which we did not test, have to be taken in account, these
results demonstrate that CNS inflammation and injury
induced by TLR2 or TLR7 activation is not exacerbated
by subsequent activation of TLR4 through the PAMP
HSP60.
Discussion
Activation of TLRs contributes to both infectious and
non-infectious CNS diseases [13]. So far, common ap-
proaches to unravel the influence of TLRs in the CNS
used mice deficient of one TLR or of their signaling
adaptors or made use of a single ligand that is highly
specific for activation of the respective TLR. However,
although the pathophysiological relevance of the differ-
ent TLR ligands for the brain has not yet been conclu-
sively clarified, it can be reasonably assumed that more
than one TLR is involved in physiological and patho-
logical processes within the CNS, and molecules that
activate TLRs are likely be present as a mixture at one
time. We sought to analyze the impact of single and
pairwise TLR activation on inflammation and neurode-
generation in the CNS.
Studies on models of systemic infectious diseases indi-
cate that TLR family members act in concert to induce
an effective antibacterial response [32,33]. This concept
of receptor redundancy certainly makes sense, especially
in the CNS, since pathogens are capable of eliciting dev-
astating consequences in a tissue that has only limited
regenerative capacity, such as the brain. Therefore, the
host repertoire of available TLRs should be substantial,
ensuring that an effective immune response will be rap-
idly induced upon infection of the CNS parenchyma. For
Figure 8 Subsequent challenge with HSP60 does not exacerbate CNS damage induced by exogenous TLR ligands. C57BL/6J mice
received two subsequent intrathecal injections. On day one 40 μL water (carrier), 40 μg Pam3CysSK4 (Pam), or 136 μg loxoribine (Lox) were
injected. After 24 h, 40 μL PBS or 40 μg HSP60 were injected additionally (water + PBS n = 7; water + HSP60 n = 4; Pam + PBS n = 5; Lox + PBS
n = 5; Pam + HSP60 n = 8; Lox + HSP60 n = 8). After a further 3 days, brains were analyzed by immunohistochemistry. (A, C) NeuN+ cells of the
cerebral cortex were quantified, and the mean is expressed as NeuN+ cells per mm2; median with Kruskal-Wallis test followed by Bonferroni
post-hoc test of control (water + PBS) vs. treatment or between the respective treatments, as indicated. P* <0.05; n.s.: not significant. (B, D) Brain
sections of injected mice were immunostained with an Ab against activated caspase-3. Cortical cells positive for activated caspase-3 were quantified.
The mean of six high power fields per cerebral cortex is expressed as caspase-3+ cells per mm2; median with Kruskal-Wallis test followed by Bonferroni
post-hoc test of control (water + PBS) vs. treatment or between the respective treatments, as indicated. P* <0.05; n.s.: not significant. (E, F) Representative
micrographs of the cerebral cortex immunostained with neurofilament Ab (NF) and Iba1 Ab to mark axons and microglia, respectively.
Scale bar, 100 μm, inset 50 μm.
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tor for gram-positive bacteria, several studies on the brain
indicate that TLR2 might be dispensable in the recogni-
tion of whole gram-positive bacteria [37]. Further, TLR
signaling in the brain must be tightly controlled in order
to respond properly to pathogens. Insufficient TLR sig-
naling may result in susceptibility of infection, whereas
excessive signaling may lead to septic shock or auto-
immune diseases. Although TLR2, TLR4, TLR7, and
TLR9 in microglia were shown to activate the canonical
pathway resulting in the production of proinflammatory
molecules [16,22], not all TLRs tested acted in synergy
in our present study. While combined stimulation of TLR4
plus TLR2 and TLR4 plus TLR9 caused additive secretion
of several inflammatory molecules, including TNF-α, IL-6,
IL-10, CXCL1, and NO from microglia compared to ac-
tivation of the respective single TLR, combined stimula-
tion with ligands specific for TLR2 and TLR9 resulted
in additive secretion of TNF-α, but did not induce such
an enhanced response for the other tested inflammatory
molecules.
The synergy of TLR4 and TLR2 activation on TNF-α
secretion has been previously observed in macrophages
[38], and it was postulated that confirmation of one
pathogen-associated molecule through another might
serve as a mechanism of safety for the organism [39]. Al-
though not determined yet, it is possible that, in com-
bination, specific TLR ligands activate both the signaling
pathway through MyD88 and the one through TRIF at
the same time [40]. This would explain why pairwise
stimulation of TLR4 (via MyD88/TRIF) plus TLR9 (via
MyD88), but not TLR2 (via MyD88) and TLR9 (via
MyD88), resulted in the enhanced secretion of multiple
inflammatory molecules from microglia in our experimen-
tal set-up. Further, the synergistic production of TNF-α
might be, at least in part, due to a prolonged half-life of
TNF-α mRNA [41], whereas the increase in NO might be
due to an enhanced iNOS mRNA expression [42]. How-
ever, autocrine and/or paracrine features of the respective
cytokine/chemokine may also contribute to an enhanced
inflammatory response [43]. The fact that additional acti-
vation of TLR7 suppressed the inflammatory response in-
duced by TLR2, TLR4, and TLR9 in microglia may result
from interactions that have been described before in both
peripheral immune cells and various cell lines. For ex-
ample, inhibition of TLR7 by TLR9 through physical
interaction was observed in HEK293 cells [44]. Ligands
of TLR7 inhibit TLR9-induced IFN-α secretion from
plasmacytoid dendritic cells and B cells, which was
found unlikely due to kinetic up-take advantages [45]
and was rather accounted to a subsequent reduced ex-
pression of the transcriptional factor IRF-7 [46]. An-
other study showed that both TLR7 and its agonist
imiquimod, independent of TLR7, can exert inhibitoryeffects on TLR9-induced cytokine responses in glial
cells [47].
While TLR7 and TLR9 primarily share the same com-
partment, namely the endosome, and TLR7 can exert a
physical effect on TLR9, TLR2, and TLR4, whose activa-
tion is impaired by simultaneous activation of TLR7 in
microglia, both TLR2 and TLR4 are primarily sited at the
cell surface. It is possible, since TLR2 and TLR4 require
recruitment of the adaptor Mal in addition to MyD88, that
TLR7 signaling is initiated faster and suppresses consecu-
tive signaling induced by TLR2 and TLR4 activation. Still,
TLR2 and TLR4 primarily located on the cell membrane
are readily available, while activation of the endosomal
TLR7 requires internalization of its ligand. On the
other hand, TLRs may compete for the same signaling
molecules and the molecular complex assembled for
TLR7 signaling may require fewer components than
the one for TLR2 and TLR4, making it faster and more
“favorable”.
Overall, we cannot rule out that specific cytokines,
chemokines, and/or neurotoxic metabolites different from
the ones investigated in our study accumulate in response
to activation of the respective TLR or that the period of
observation in our set-up was too short. Additionally,
expression of distinct inflammatory molecules in the
brain may depend on the concentrations of the different
TLR ligands, which we did not test entirely. Finally, it
has to be taken into account that microglia easily and
rapidly change from a resting to an activated status,
since they are extremely sensitive to virtually any change
in their environment [48]. As a consequence, the extent of
inflammatory responses may vary slightly between differ-
ent experiments, depending on the activation status of the
respective cell preparation.
Neuronal injury mediated via activation of TLR2 [28],
TLR4 [20], and TLR9 [29] expressed in microglia has
been described in vitro. In addition, activation of TLR7
in neurons results in cell-autonomous and microglia-
mediated neurodegeneration [7]. Proinflammatory media-
tors, such as TNF-α [29] and NO [18], reveal neurotoxic
effects in the context of TLR-induced neuronal injury via
activation of microglia. However, to our knowledge, the
impact of combined TLR stimulation on neuronal survival
in the CNS has not been systematically studied so far. The
impact of specific pairwise TLR stimulation in microglia
on the inflammatory response and subsequent neuronal
injury compared to activation of a single TLR is clearly
reflected by the results from our present studies. For ex-
ample, specific activation of both TLR4 and TLR2 revealed
a synergistic effect on enhancing the inflammatory re-
sponse and on reducing neuronal viability. However, this
effect was only seen if the PAMP LPS was used for TLR4
activation. The fact that the host-derived TLR4 ligand
HSP60 did not enhance the inflammatory response and/or
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point to different intracellular signaling pathways trig-
gered by LPS and HSP60 via the same TLR. However,
these results indicate that, in principle, simultaneous acti-
vation of specific TLRs in the CNS can exert a detrimental
effect on neuronal survival through an exaggerated in-
flammatory response.
In line with the concept of an exaggerated innate im-
mune response in pathological states of the CNS, per-
manent intracerebral infusion of CpG ODN leads to
pronounced microglial activation and axonal injury
dependent on TLR9 [49]. Additionally, systemic stimula-
tion of TLR4 with LPS prior to a sub-clinical hypoxic-
ischemic insult causes severe loss of axons and neurons
in mice [20]. Furthermore, stroked mice that received an
intracerebral injection of high-mobility group box-1, an-
other host-derived TLR4 ligand besides HSP60, display
an increased edema, infarct area, and enhanced neurologic
deficits compared to animals without this additional injec-
tion [50]. In the latter cases, mice deficient of TLR4 are
protected against the respective CNS injury, indicating
that additional TLR4 activation to the initial ischemic in-
sult is detrimental. In our study, we set up an experiment
in which the murine brain was challenged by the DAMP
HSP60, a TLR4 agonist, after initial treatment with the re-
spective pathogen-associated ligands for TLR2 or TLR7.
Notably, we have demonstrated in previous work that
neurotoxic effects mediated by HSP60 are not caused by
contamination with LPS [18]. In the current study, mice
displayed considerable loss of neurons and/or injury of
axons in the brain if challenged by intrathecal HSP60 or
the respective ligands for TLR2 and TLR7 alone. However,
additional injection of HSP60 failed to deteriorate initial
CNS injury induced by TLR2 or TLR7 activation. It is pos-
sible that these findings reflect the tolerance paradigm
observed in several studies, in which immune cells stimu-
lated with a TLR ligand react hyporesponsively to subse-
quent TLR activation [38,51]. A similar phenomenon
termed pre-conditioning is frequently observed in the is-
chemic CNS. In this context, the murine brain is resistant
to an ischemic insult, which occurs subsequently to a pre-
vious mild ischemic insult. This effect can be induced by
prior challenge with LPS or other forms of sub-clinical
stress. In the context of an experimental pre-conditioning
event, systemic application of LPS, Pam3CysSK4, or CpG
ODN, activating TLR4, TLR2, and TLR9, respectively,
prior to an experimental stroke results in protection of the
mouse brain [52-55]. Accordingly, TNF-α released after
the primary stimulus was found to exert a regulatory ef-
fect on neuroprotection [53,54]. Mice lacking TLR4 re-
ceiving pre-conditioning prior to permanent cerebral
ischemia are not protected and show reduced NF-κB acti-
vation and lower expression levels of TNF-α compared to
wild-type animals [56].Overall, these studies point to a complex modulation
of inflammatory processes, protecting the brain from
further damage mediated by inflammation to come. A
variety of inhibitory strategies in TLR signaling in im-
mune cells causing tolerance to subsequent stimulation
have been elucidated. For example, signaling molecules
are degraded or dissociation from another is decreased
whereas expression of inhibitory proteins is enhanced
[57]. Our finding that intrathecal HSP60 does not induce
morphologic characteristics suggestive of activation of
microglia in vivo does not exclude a contribution of micro-
glia to neuronal injury, as was reported in our previous
in vitro studies [18]. Subtle activation of glial cells in vivo
likely occurs, as these cells constantly monitor their micro-
environment [58], even though their gross morphology is
unchanged. Furthermore, inflammatory responses induced
by HSP60 through TLR4 and TLR2 in peripheral immune
cells are dependent on the respective pathological context
in vivo [59], a finding that is likely to apply to microglia
as well. The finding that intrathecal LPS does not lead
to significant loss of neurons in the cerebral cortex while
such neurodegenerative effects occur in co-cultures of
microglia and neurons [20] suggests that the situation in
the brain in vivo is likely a lot more complex.
Conclusions
Based on our results we conclude that the outcome of
neuroinflammation and neuronal injury induced by an
activated innate immune system in the CNS depends, at
least in part, on the identity and combination of the TLR
family members engaged. While activation of each of the
tested TLRs provoked an inflammatory response in micro-
glia and stimulation of selected TLRs caused neuronal
damage, the extent and pattern of such a response was
modified specifically by the TLR ligand used, the num-
ber and combination of activated TLRs, and the timing.
Although all tested TLRs share common signaling path-
ways, not all of them synergized but also antagonized
one another when activated simultaneously. A detailed
understanding of the innate immunity’s action and
mechanisms of fine-tuning the inflammatory response
involved in both CNS homeostasis and disorders is es-
sential and may pave the way for new preventive and
therapeutic strategies.
Additional files
Additional file 1: Figure S1. Secretion of TNF-α from microglia and
viability of neurons in response to different TLR ligands. (A) Purified
microglia from C57BL/6J mice were incubated for 6 h with various doses
of LPS, Pam3CysSK4 (Pam), loxoribine (lox), CpG ODN (CpG), or HSP60, as
indicated. PBS served as control. Supernatants were analyzed by TNF-α
ELISA. Results are presented as mean ± SEM of three independent experiments
run with duplicates. n.d., not detected. (B) Cortical neurons from C57BL/6J
mice were incubated for 6 h with various doses of LPS, Pam3CysSK4 (Pam),
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http://www.jneuroinflammation.com/content/11/1/166loxoribine (lox), CpG ODN (CpG), or HSP60, as indicated. PBS served as
control. Subsequently, cultures were immunostained with NeuN Ab to mark
neurons, and NeuN-positive cells per field were quantified. P* < 0.05,
P** < 0.005, ANOVA with Bonferroni-selected two pairs of each dose of the
respective ligand vs. control, as indicated. Results are presented as
mean ± SEM of three independent experiments run with duplicates.
Additional file 2: Figure S2. The TLR3-specific ligand poly(I:C) does not
suppress TNF-α secretion from microglia incubated with other TLR ligands.
(A) Purified microglia from C57BL/6J mice were incubated for 6 h with
various doses of poly(I:C), as indicated. PBS served as control. Supernatants
were analyzed by TNF-α ELISA. Results are presented as mean ± SEM of
three independent experiments run with duplicates. n.d., not detected.
(B) Purified microglia from C57BL/6J mice were incubated for 6 h with
LPS (100 ng/mL), Pam3CysSK4 (Pam, 100 ng/mL), CpG ODN (CpG, 1 μM),
or poly(I:C) (1 μg/mL) alone or simultaneously with pairwise combinations
of the ligands, as indicated. PBS served as control. Supernatants were
analyzed by TNF-α ELISA. Results are presented as mean ± SEM of
three independent experiments run with duplicates. ANOVA with two
Bonferroni-selected pairs of each individual ligand vs. ligand combination,
as indicated. P** < 0.005, P*** < 0.001, n.s., not significant.
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